This article highlights some of the key takeaways of a webinar sponsored by Datavant. The webinar included a panel of representatives from leading companies in pharmaceutical marketing and technology, each bringing unique perspectives on marketing trends, data, compliance, activation and strategy: Scott Ronay, Partnerships, Datavant Joe Kotz, SVP Product Sales, VideoAmp Ted Sweetser VP of…

The value of real-world data (RWD) and real-world evidence (RWE) for pharmaceutical companies goes far beyond clinical and drug development applications, such as clinical trial feasibility studies, manufacturing, health economic and outcomes research and medical affairs. These datasets are also recognized as critical tools for shaping effective marketing and commercial strategies. The importance of real-world…

More than a year has passed since Humira biosimilars were launched in the US, and with these, several other biosimilar drug approvals that either directly compete with Humira or are indicated for other rare immunologic conditions, macular degeneration, and oncology and hematological disease.  Ongoing industry surveillance of biosimilars and the   Source: “Biosimilars are becoming more widely available,…

The research is clear: Data drives better health outcomes.  Data has the power to transform how healthcare is delivered and guide organizations toward more patient-centered, value-driven care. Even though data is abundant, it’s often siloed or delivered in disparate data sets, and companies commonly lack the necessary resources to turn the data into insights.   Making…

A recent survey from Mercer highlighted a growing trend among large employers- the search for alternative health plan options to address rising healthcare costs. The survey focused on a number of the most important factors for employers looking to increase the potential for cost savings while maintaining a competitive benefits package – designing high-performance networks…

PurpleLab® is driven by a singular goal – to provide healthcare organizations with robust and accessible real-world data (RWD) and real-world evidence (RWE) to solve conventional and emerging challenges, including tackling medication adherence. According to the FDA[1], real-world evidence (RWE) is defined as “the clinical evidence that looks at the usage and potential benefits or…

This blog is part four in a series exploring the use of real-world evidence to produce meaningful insights in clinical pharma.  Medical affairs is a department within pharmaceutical companies that focuses on communicating scientific and clinical information to healthcare providers. Pharmaceutical medical affairs teams are responsible for activities that bridge the gap between the development…

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications frequently used to treat type 2 diabetes mellitus (T2DM) and obesity.[1] This class of medications assists in lowering blood sugar levels and promotes weight loss. In addition to treating diabetics, these medications are also used to treat obesity in diabetics as well as non-diabetics.   GLP-1 drugs…

This blog is part three in a series exploring the use of real-world evidence to produce meaningful insights in clinical pharma.  Health Economics and Outcomes Research (HEOR) is a field that determines the cost-effectiveness of drugs, medical devices and other healthcare interventions. It analyzes data from various sources to build evidence around the value of…